Selection of Oncology and Kinome Profiling publications (2021-23)

PamGene's recent publications highlighting fundamental and discovery, plus biomarker and clinical research Applications.
A representative list from 300+ publications can be found at https://pamgene.com/publications/.



Kinome profiling identified biomarkers, to predict response to ICIs in melanoma and lung cancer: A basis of our IOpener® IVD

(Link)



Kinome profiling showed that Gemcitabine counteracts Oxal-chemoresistance by strongly inhibiting Akt and Src/ p38 MAPK pathways

(Link)



Kinome profiling showed Src family and PI3K pathway were inhibited by TKIs to different extent, implying treatment options for select RCC patients

(Link)



Kinome profiling showed that AATK acts a Ser/Thr kinase that phosphorylates TP53, represses growth through CyclinD1 and WEE1

(Link)



Kinome profiling showed that CDK8/CDK19 inhibition resulted in reduced migration and increased adhesion in prostate cancer

(Link)



Kinome profiling showed that combined treatment with AKT and mTOR inhibitors leads to synergistic reduction in proliferation of EpCAM+ and CD90+ HCC cells

(Link)



BTK expression within GBM tissue was linked to longer patient survival, with implications for the design and interpretation clinical trials using BTK inhibitors

(Link)



Kinome profiling of HNSCC patients identified Src family kinases to be hyperactivated, associated as biomarker to poor prognosis and potential therapeutic target

(Link)



Kinome profiling with computational modelling allows for a broad assessment of kinase networks in complex disease models and for potential drug targets

(Link)